Results 161 to 170 of about 43,858 (197)

JAK inhibitor tofacitinib alleviates secretory dysfunction and Th17/Treg imbalance in a Sjögren's disease murine model. [PDF]

Ann Med
Lin Y, Ou Y, Su J, Xu J, Liu C, He K, Zhou L, Wu D, Chen J.   +8 more
europepmc   +1 more source

A Comparative Study of Oral Tofacitinib and Oral Methotrexate in the Treatment of Patients With Moderate to Severe Chronic Plaque Psoriasis. [PDF]

Cureus
Unnikrishnan P, Vudayana K, Chintada D, Khatija Begum M, Chalamalasetty SS, Gullipalli P.   +5 more
europepmc   +1 more source

Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review. [PDF]

Front Immunol
Wan Z, Wang Y, Yang D.
europepmc   +1 more source

Authors' Response to Comment on published article "A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale". [PDF]

Indian Dermatol Online J
Sardana K, Sharath S, Meena SK, Khurana A, Dhir B.   +4 more
europepmc   +1 more source

Multimodal Approach for Recalcitrant Melasma Using Picosecond Laser and Topical JAK Inhibition: A Case Report. [PDF]

J Cosmet Dermatol
Ashkanani H, AlZaabi M, AlRasheed A, AlDaraji W.   +3 more
europepmc   +1 more source

Clinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis. [PDF]

J Cosmet Dermatol
Shu C, Zhang T, Liu JW, Zhu CY, Fang RY, Sun QN, Li N, Li F.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tofacitinib

Reactions Weekly
Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal ...
  +16 more sources

Tofacitinib

Reactions Weekly, 2023
  +8 more sources